Proven Answers for Protein, Vaccine and Gene Therapy Analysis

Proven answers for protein, vaccine and gene therapy analysis

Rapid growth in the cell and gene therapy industry has generated an urgent need for robust analytics around characterization of both vectors and nucleic acid biotherapeutics such as oligonucleotides, plasmid DNA, small RNA, mRNA and double stranded DNA.

In this webinar, we demonstrate multiple key analytical workflows that can be performed for extensive characterization of AAV. Some of these methodologies include AAV capsid purity analysis (VP1, VP2 and VP3). In addition, a suite of analytical methods recently developed and optimized for characterization of the nucleic acid biotherapeutics and detection of impurities.

You will:

  • Discover solutions for sizing, purity, and sequence analysis of your cell and gene therapeutics
  • Easily analyze a wide range of nucleic acids, viral capsids, and proteins all on one platform
  • Increase data confidence with robust solutions utilizing industry and regulatory proven technology

Who should attend:

  • Lab scientists or managers developing gene therapies
  • Those interested in analytical solutions for vectors and nucleic acid biotherapeutics such as oligonucleotides, plasmid DNA, small RNA, mRNA and double stranded DNA

Speaker

RUO-MKT-11-10857-A

Watch On-Demand